Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukemia: A randomised phase 3 trial
The Lancet Oncology,  Clinical Article

Elter T et al. – The combination of fludarabine and alemtuzumab is another treatment option for patients with previously treated CLL.

Methods

  • Patients (aged ≥18 years) with CLL Binet stage A, B, or C or Rai stages I—IV were randomly assigned in a 1:1 ratio according to a computer-generated allocation schedule to open-label combination treatment (fludarabine 30 mg/m2 per day and alemtuzumab 30 mg per day on days 1—3) or monotherapy (fludarabine 25 mg/m2 on days 1—5) by use of an interactive voice response system
  • Both regimens were given intravenously for a maximum of six 28-day cycles
  • Primary endpoint was PFS
  • Analysis was by intention to treat

Results

  • Fludarabine plus alemtuzumab (n=168) resulted in better PFS than did fludarabine monotherapy (n=167; median 23·7 months [95% CI 19·2—28·4] vs 16·5 months [12·5—21·2]; HR 0·61 [95% CI 0·47—0·80]; p=0·0003) and OS (median not reached vs 52·9 months [40·9—not reached]; 0·65 [0·45—0·94]; p=0·021) compared with fludarabine alone
  • All-cause AEs occurred in 161 (98%) of 164 patients in combination treatment group and 149 (90%) of 165 in the fludarabine alone group
  • Patients in fludarabine plus alemtuzumab group had more cytomegalovirus events (23 [14%] vs one [<1%]) and grade 1 or 2 potentially alemtuzumab infusion-related adverse reactions (102 [62%] vs 22 [13%])
  • Grade 3 or 4 toxicities in combination treatment and monotherapy groups were leucopenia (121 [74%] of 164 vs 55 [34%] of 164), lymphopenia (149 [94%] of 158 vs 53 [33%] of 161), neutropenia (93 [59%] of 157 vs 110 [68%] of 161), thrombocytopenia (18 [11%] of 164 vs 27 [17%] of 163), and anaemia (14 [9%] of 163 vs 28 [17%] of 164)
  • Incidence of serious AEs was higher in combination treatment group (54 [33%] of 164 vs 41 [25%] of 165); deaths due to AEs were similar between 2 groups (10 [6%] vs 12 [7%])

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study Journal of Clinical Oncology, July 17, 2014

2 Calcium, vitamin D, dairy products, and mortality among colorectal cancer survivors: The Cancer Prevention Study-II Nutrition Cohort Journal of Clinical Oncology, July 9, 2014    Clinical Article

3 Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial The Lancet Oncology, March 7, 2014    Clinical Article

4 Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: The EVOLVE-1 randomized clinical trial JAMA, July 7, 2014    Evidence Based Medicine    Clinical Article

5 Coffee intake and gastric cancer risk Cancer Epidemiology, Biomarkers & Prevention, March 20, 2014    Clinical Article

6 Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia New England Journal of Medicine, June 4, 2014    Evidence Based Medicine    Clinical Article

7 Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial The Lancet, July 25, 2014    Evidence Based Medicine    Clinical Article

8 Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA) Journal of Clinical Oncology, May 29, 2014    Clinical Article

9 Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: a cross-trial comparison of two phase III trials Lung Cancer, July 22, 2014    Clinical Article

10 A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer European Journal of Cancer, May 23, 2014    Clinical Article

11 Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: The FACS randomized clinical trial Full Text JAMA, January 16, 2014    Free full text    Evidence Based Medicine    Clinical Article

12 Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992–2008 American Journal of Epidemiology, July 18, 2014    Clinical Article

13 The association of vitamin D supplementation with the risk of cancer in postmenopausal women Cancer Causes and Control, December 18, 2013    Clinical Article

14 Dietary one-carbon nutrient intake and risk of lymphoid and myeloid neoplasms: Results of the Netherlands Cohort Study Cancer Epidemiology, Biomarkers & Prevention, July 29, 2014    Clinical Article

15 Body mass index, diabetes, and triple-negative breast cancer prognosis Breast Cancer Research and Treatment, July 8, 2014

16 Diagnosis and treatment of disseminated intravascular coagulation International Journal of Laboratory Hematology, May 5, 2014    Review Article

17 Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials The Lancet, March 25, 2014    Evidence Based Medicine    Clinical Article

18 Regular aspirin use and risk of multiple myeloma: A prospective analysis in the Health Professionals Follow-up Study and Nurses' Health Study Cancer Prevention Research, December 26, 2013    Clinical Article

19 Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival – Results from a prospective, observational study in Germany The Breast, July 24, 2014

20 Association between melanocytic nevi and risk of breast diseases: The French E3N Prospective Cohort Full Text PLoS Medicine, July 2, 2014    Free full text    Evidence Based Medicine    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close